2 recruiting, 1 active not recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Mivelsiran: new trials by email Literature Review of Mivelsiran trials Research Report on Mivelsiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Mivelsiran, Placebo - Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Phase 2 | Recruiting | Alnylam Pharmaceuticals | 58 | 2026-08-17 | 2026-10-13 |
| A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy Placebo, ALN-APP - Cerebral Amyloid Angiopathy | Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 210 | 2024-05-17 | 2026-10-20 |
| A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD ALN-APP, Placebo - Early-Onset Alzheimer Disease | Phase 1 | Recruiting | Alnylam Pharmaceuticals | 60 | 2022-02-04 | 2026-10-20 |
Alzheimer Disease (1) · Cerebral Amyloid Angiopathy (1) · Down Syndrome (1)
United States (3) · Canada (2) · Netherlands (2) · United Kingdom (2) · Australia (1) · Spain (1) · Switzerland (1)
2023 (2), 2025 (1)